MedTrace Logo

Inhaled Sedation in Critically Ill Patients

NCT07000526 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 620

Last updated 2026-05-19

No results posted yet for this study

Summary

The proposal of this study is to compare inhaled sedation with isoflurane administered via the Sedaconda ACD-S system with intravenous sedation with propofol. Patients will be randomized 1:1 to receive either inhaled sedation with isoflurane administered via the Sedaconda ACD device (Sedana Medical, Uppsala, Sweden) or intravenous propofol. The primary endpoint is the number of ventilator-free days at 28 days after randomization.

Conditions

  • Sedation
  • Airway Extubation

Interventions

DRUG

Isoflurane

Inhaled sedation with isoflurane via Sedaconda ACD-S

DRUG

Propofol

Intravenous sedation with Propofol 20 mg/ml

Sponsors & Collaborators

  • Instituto de Salud Carlos III

    collaborator OTHER_GOV

  • Instituto de Investigación Hospital Universitario La Paz

    lead OTHER

Principal Investigators

  • José M. Añón, MD, PhD · Hospital Universitario La Paz. IdiPAZ

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-15
Primary Completion
2027-03-31
Completion
2027-12-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07000526 on ClinicalTrials.gov